CLOV Stock Recent News

WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025.

I remain bullish on Clover Health long-term but prefer to Hold until Q4 2024 earnings for higher conviction before initiating a long position in this stock. I believe the 40% YTD rise and 60% retail ownership increase the risk of profit taking post-earnings, similar to the Q3 panic selloff. On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 lives, with 95% in its 4-Star PPO plan.

Clover Health Investments, Corp. is a healthcare provider focused on providing Medicare Advantage plans to seniors. The company's proprietary AI technology helps drive higher reimbursement rates and lower cost of care. The company is leaning into demographic and consumer preference tailwinds giving it a unique competitive advantage.

Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform.

Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.

WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover's flagship 4-Star PPO plan.

WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”).

Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating

Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience

Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health